Detalhe da pesquisa
1.
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
Invest New Drugs
; 37(1): 147-158, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30056611
2.
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.
Cancer Chemother Pharmacol
; 87(2): 185-196, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33145616
3.
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
J Pharmacokinet Pharmacodyn
; 37(4): 347-63, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20652729
4.
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Invest New Drugs
; 27(2): 140-52, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18712503
5.
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug-Drug Interaction Studies in Healthy Subjects.
Clin Pharmacol Drug Dev
; 7(6): 597-612, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29870596
6.
A Randomized, Placebo-Controlled, Double-Blind Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeated Doses of Mirogabalin in Healthy Asian Volunteers.
Clin Pharmacol Drug Dev
; 7(6): 661-669, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29663714
7.
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Cancer Chemother Pharmacol
; 77(5): 987-96, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27017616
8.
Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer.
J Clin Oncol
; 33(24): 2609-16, 2015 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-26124477
9.
Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog.
Int J Pharm
; 276(1-2): 75-81, 2004 May 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-15113616
10.
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Clin Cancer Res
; 15(12): 4207-12, 2009 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19509177